Food and Drug Administration
Dermatologic and Ophthalmic Drugs Advisory Committee
November 4, 2002
Briefing Information
Table of Contents HTM PDF Word
Executive Summary HTM PDF Word
Acne Global Severity Scale HTM PDF Word
Efficacy Evaluation in Acne Clinical Trials HTM PDF Word
Inflammatory Lesions by Visit, Plot 1A PDF Excel
Inflammatory Lesions by Visit, Plot 1B PDF Excel
Non-Inflammatory Lesions by Visit, Plot 2 PDF Excel
Total Lesions by Visit, Plot 3 PDF Excel
Inflammatory Lesions Over Cycle, Plot 4 PDF Excel
Non-Inflammatory Lesions by Cycle, Plot 5 PDF Excel
Total Lesions by Cycle, Plot 6 PDF Excel
Inflammatory Lesions at week 12 by Baseline, Plot 7 PDF Excel
Non-Inflammatory Lesions at week 12 by Baseline, Plot 8 PDF Excel
Total Lesions at week 12 by Baseline, Plot 9 PDF Excel
Inflammatory Lesions at Cycle 6 by Baseline, Plot 10 PDF Excel
Non-Inflammatory Lesions at Cycle 6 by Baseline, Plot 11 PDF Excel
Total Lesions at Cycle 6 over Baseline, Plot 12 PDF Excel
Combination Topical Products for the Treatment of Acne Vulgaris HTM PDF Word